Shaolin Capital Management’s Orchestra BioMed OBIO Stock Holding History

Shaolin Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-200,000	Closed	-$1.98M	–	976
2022 Q1	$1.98M	Buy	200,000 +150,000	+300%	+$1.48M	0.05%	404
2021 Q4	$504K	Hold	50,000	–	–	0.01%	490
2021 Q3	$495K	Hold	50,000	–	–	0.02%	382
2021 Q2	$510K	Hold	50,000	–	–	0.02%	399
2021 Q1	$560K	Hold	50,000	–	–	0.02%	376
2020 Q4	$641K	Hold	50,000	–	–	0.05%	224
2020 Q3	$550K	Buy	+50,000	New	+$561K	0.04%	172

Other funds holding OBIO

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Amitell Capital Singapore $62.4M AUM 75.98% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Centiva Capital New York $13.6B AUM 20% 1-Year Est. Return

Shaolin Capital Management's OBIO Position: Q2 2022 in Review

Shaolin Capital Management sold out of Orchestra BioMed (OBIO) in Q2 2022, closing a stake of 200,000 shares — an estimated $1.98M sold.

Shaolin Capital Management first reported a position in OBIO in Q3 2020 and held it in 7 quarters. The position peaked at $1.98M in Q1 2022. 62 funds tracked by Wall St. Rank hold OBIO as of Q2 2022.

Shaolin Capital Management reported no remaining Orchestra BioMed position as of Q2 2022 after selling out during the quarter.
Shaolin Capital Management sold 200,000 Orchestra BioMed shares in Q2 2022, an estimated $1.98M.
Shaolin Capital Management first reported a position in Orchestra BioMed in Q3 2020 and held it in 7 quarters.
Shaolin Capital Management's Orchestra BioMed position peaked at $1.98M in Q1 2022.
62 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2022.

Based on Shaolin Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.